Tags : Jounce Therapeutics

Jounce Stops Enrollment in P-II EMERGE Study Evaluating Vopratelimab for

Shots: The company will not expand the P-II EMERGE study that assesses Vopratelimab + ipilimumab in PD-(L)1 inhibitor experienced NSCLC patient. Early evaluation of the study showed that the trial will not meet pre-specified interim criteria for continuation of enrollment The company also reported the first patient dosing in P-II SELECT study assessing Vopratelimab + […]Read More

Celgene Reports Update on its Collaboration with Jounce Therapeutics

Shots: Jounce to receive $50M up front, $180M as development & regulatory milestones, $300M as commercial milestones, royalties on global sales and will retain WW rights to its pipeline including vopratelimab, JTX-4014 and all discovery programs Celgene to get WW rights to develop & commercialize Jounce’s JTX-8064, an anti-leukocyte immunoglobulin like receptor B2 (LILRB2) Ab, […]Read More